News
Zacks Investment Research on MSN17d
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart DrugMerck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals ...
Hosted on MSN1mon
Merck & Co., Inc. (MRK): Among the Cheap Pharmaceutical Stocks to Buy According to AnalystsWe recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...
Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...
Collis, David J. "Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)." Harvard Business School Teaching Note 713-450, March 2013.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback